JP2016512205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512205A5 JP2016512205A5 JP2015561930A JP2015561930A JP2016512205A5 JP 2016512205 A5 JP2016512205 A5 JP 2016512205A5 JP 2015561930 A JP2015561930 A JP 2015561930A JP 2015561930 A JP2015561930 A JP 2015561930A JP 2016512205 A5 JP2016512205 A5 JP 2016512205A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- analog
- analogue
- pharmaceutical composition
- fasting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 57
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 210000004153 islets of langerhan Anatomy 0.000 claims 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
- 102000004877 Insulin Human genes 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000008103 glucose Substances 0.000 claims 8
- 229940125396 insulin Drugs 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000001737 promoting effect Effects 0.000 claims 7
- 230000007812 deficiency Effects 0.000 claims 6
- 230000008929 regeneration Effects 0.000 claims 6
- 238000011069 regeneration method Methods 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 5
- 201000009104 prediabetes syndrome Diseases 0.000 claims 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000016097 disease of metabolism Diseases 0.000 claims 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 4
- 201000008980 hyperinsulinism Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 210000005036 nerve Anatomy 0.000 claims 3
- 230000004112 neuroprotection Effects 0.000 claims 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 108010075254 C-Peptide Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000291 postprandial effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 229930195729 fatty acid Chemical class 0.000 claims 1
- 239000000194 fatty acid Chemical class 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072771 | 2013-03-15 | ||
| PCT/CN2013/072771 WO2014139182A1 (en) | 2013-03-15 | 2013-03-15 | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| PCT/CN2014/073483 WO2014139472A1 (en) | 2013-03-15 | 2014-03-14 | Compositions and methods of using islet neogenesis peptides and analogs thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225049A Division JP7075918B2 (ja) | 2013-03-15 | 2019-12-13 | 膵島新生ペプチド及びその類似体を使用する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512205A JP2016512205A (ja) | 2016-04-25 |
| JP2016512205A5 true JP2016512205A5 (cg-RX-API-DMAC7.html) | 2017-04-20 |
| JP6674258B2 JP6674258B2 (ja) | 2020-04-01 |
Family
ID=51535856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561930A Active JP6674258B2 (ja) | 2013-03-15 | 2014-03-14 | 膵島新生ペプチド及びその類似体を使用する組成物及び方法 |
| JP2019225049A Active JP7075918B2 (ja) | 2013-03-15 | 2019-12-13 | 膵島新生ペプチド及びその類似体を使用する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225049A Active JP7075918B2 (ja) | 2013-03-15 | 2019-12-13 | 膵島新生ペプチド及びその類似体を使用する組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US20160039877A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3473642B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6674258B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102244349B1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014231444B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015022469A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2906240C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2703110T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL241383B (cg-RX-API-DMAC7.html) |
| MX (2) | MX378245B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ711958A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2685958C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201507404RA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014139182A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4560952B2 (ja) * | 1999-12-03 | 2010-10-13 | 株式会社セガ | ゲーム装置及びゲームシステム |
| CN105492459A (zh) * | 2013-02-15 | 2016-04-13 | 高端学术皇家研究会/麦吉尔大学 | 用于治疗糖尿病的修饰的ingap肽 |
| CN108697815A (zh) * | 2016-02-10 | 2018-10-23 | 辉瑞公司 | 具有egfr配体的治疗性纳米颗粒及其制备和使用方法 |
| CN108616978B (zh) * | 2016-12-14 | 2022-04-15 | 中兴通讯股份有限公司 | 一种网络功能实体进行无状态处理的方法及装置 |
| KR102006890B1 (ko) * | 2016-12-27 | 2019-08-05 | 한양대학교 산학협력단 | 췌장 소도 세포 표적 펩타이드 및 이의 용도 |
| CA3063183A1 (en) * | 2017-05-11 | 2019-12-03 | Shenzhen Hightide Biopharmaceutical, Ltd. | Use of peptide compounds in treating acute pancreatitis |
| US20190142901A1 (en) * | 2017-11-16 | 2019-05-16 | Claresa Levetan | Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies |
| CN114644683B (zh) * | 2018-09-18 | 2023-09-12 | 广州领晟医疗科技有限公司 | 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途 |
| KR101995768B1 (ko) | 2019-03-13 | 2019-07-03 | (주)엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
| WO2021222831A2 (en) * | 2020-05-01 | 2021-11-04 | The Broad Institute, Inc. | Engineered central nervous system compositions |
| EP4469467A4 (en) * | 2022-01-25 | 2025-10-29 | Shenzhen Hightide Biopharmaceutical Ltd | COMPOSITIONS AND METHODS FOR TREATING CYTOKIN SHOCK |
| WO2024169938A1 (en) * | 2023-02-16 | 2024-08-22 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for treating liver diseases |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661187B1 (fr) | 1990-04-20 | 1994-08-05 | Inst Nat Sante Rech Med | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. |
| FR2700011B1 (fr) | 1992-12-24 | 1995-02-24 | Inst Nat Sante Rech Med | Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP. |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US5834590A (en) | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5804421A (en) | 1996-10-30 | 1998-09-08 | Eastern Virginia Medical School Of The Medical College Fo Hampton Roads | High level of expression of ingap in bacterial and euraryotic cells |
| US5935813A (en) | 1997-03-20 | 1999-08-10 | Incyte Pharmaceuticals, Inc. | Human pancreatitis-associated protein |
| US20020052308A1 (en) | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US20040018623A1 (en) | 1999-10-29 | 2004-01-29 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
| US20020009730A1 (en) | 1999-11-17 | 2002-01-24 | Alex Chenchik | Human stress array |
| CA2343602A1 (en) | 2000-04-18 | 2001-10-18 | Genset | Est's and encoded human proteins |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
| DE10056802B4 (de) | 2000-11-14 | 2005-06-16 | Epigenomics Ag | Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik |
| CN100580084C (zh) | 2000-12-13 | 2010-01-13 | 阿纳福公司 | 具有c型类凝集素结构域的支架结构的蛋白质组合文库 |
| US20030235882A1 (en) | 2000-12-19 | 2003-12-25 | Shimkets Richard A. | Novel nucleic acids and polypeptides and methods of use thereof |
| US20040018970A1 (en) | 2000-12-19 | 2004-01-29 | Shimkets Richard A. | Novel nucleic acids and polypeptides and methods of use thereof |
| US6986994B2 (en) | 2001-01-09 | 2006-01-17 | Gmp Endotherapeutics, Inc. | INGAP displacement assays |
| US20040158036A1 (en) | 2001-03-01 | 2004-08-12 | Lawrence Rosenberg | Neuritogenic compound and uses thereof |
| EP1478772A2 (en) | 2001-08-14 | 2004-11-24 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
| US20040132644A1 (en) * | 2001-10-16 | 2004-07-08 | The Procter & Gamble Company | Composition and method for treating diabetes |
| CA2675409A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| US20060194265A1 (en) | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7662768B2 (en) | 2002-01-11 | 2010-02-16 | Mcgill University | Transdifferentiation of pancreatic acinar cells |
| US7166439B2 (en) | 2002-03-01 | 2007-01-23 | Gmp Endotherapeutics, Inc. | Assay for anti-INGAP antibodies |
| US20070015271A1 (en) | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| US20040018522A1 (en) | 2002-05-09 | 2004-01-29 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with multiple sclerosis |
| WO2003094958A1 (en) | 2002-05-09 | 2003-11-20 | Medtronic Minimed, Inc. | Immunoprotective methods for beta cell neogenesis |
| EP1523577A2 (en) | 2002-07-10 | 2005-04-20 | Oncotherapy Science, Inc. | Method for diagnosis of intestinal-type gastric tumors |
| JP2004065120A (ja) | 2002-08-07 | 2004-03-04 | Sumitomo Pharmaceut Co Ltd | 炎症性腸疾患の疾患マーカー及びその利用 |
| WO2004020588A2 (en) | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| WO2004037277A2 (en) | 2002-10-24 | 2004-05-06 | Mcgill University | Use of ingap for reversing diabetes |
| AU2003294828A1 (en) | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
| US7510708B2 (en) | 2003-04-14 | 2009-03-31 | Washington University | Disruption of the REG pathway |
| EP1488798A1 (en) * | 2003-06-18 | 2004-12-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure |
| WO2005113812A2 (en) | 2004-04-23 | 2005-12-01 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US20050277593A1 (en) | 2004-05-24 | 2005-12-15 | Washington University | Therapeutic uses of Reg protein |
| JP2008512086A (ja) | 2004-06-04 | 2008-04-24 | ワイス | 喘息治療薬としてのＲｅｇＩＩＩ蛋白質の阻害物質 |
| KR100639677B1 (ko) | 2004-11-08 | 2006-10-30 | 삼성전자주식회사 | 위상 및 지연 동기 루프와 이를 구비한 반도체 메모리 장치 |
| KR100664586B1 (ko) | 2004-12-22 | 2007-01-04 | 김현기 | 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포 |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| EA013821B1 (ru) * | 2005-05-25 | 2010-08-30 | Кьюрдм, Инк. | Проостровковые пептиды человека, их производные и аналоги и способы их применения |
| DK3524261T5 (da) | 2005-08-19 | 2024-09-02 | Amylin Pharmaceuticals Llc | Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt |
| US7807459B2 (en) | 2005-09-27 | 2010-10-05 | Reneuron, Inc. | EphA4-positive human adult pancreatic endocrine progenitor cells |
| EP1945263A4 (en) | 2005-11-09 | 2012-09-26 | Ontherix Inc | THERAPEUTIC PEPTIDES BINDING TO METALS |
| US20080039393A1 (en) | 2005-11-09 | 2008-02-14 | Desmond Mascarenhas | Metal-binding therapeutic peptides |
| WO2007071437A2 (en) | 2005-12-22 | 2007-06-28 | Ares Trading S.A. | Compositions and methods for treating inflammatory disorders |
| US20090269313A1 (en) | 2006-07-19 | 2009-10-29 | Diakine Therapeutics, Inc. | Encapsulation system |
| KR20060089873A (ko) | 2006-07-25 | 2006-08-09 | 김현기 | 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포 |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| WO2008085601A2 (en) | 2006-11-02 | 2008-07-17 | Genizon Biosciences Inc. | Genemap of the human genes associated with asthma disease |
| US8785400B2 (en) | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
| WO2008079406A2 (en) | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Gene expression markers for inflammatory bowel disease |
| FR2910311B1 (fr) | 2006-12-20 | 2009-02-13 | Oreal | Composition comprenant un compose silicone et un organosilane particulier |
| US7923014B2 (en) | 2007-02-12 | 2011-04-12 | The Board Of Regents Of The University Of Texas System | Expression and purification of HIP/PAP and uses therefor |
| AU2008230861A1 (en) * | 2007-03-26 | 2008-10-02 | Salutria Pharmaceuticals, Llc | Methods and compositions of derivatives of probucol for the treatment of diabetes |
| WO2008118946A1 (en) | 2007-03-27 | 2008-10-02 | Atherogenics, Inc. | Methods and compositions using certain phenolic derivatives for the treatment of diabetes |
| EA201000399A1 (ru) * | 2007-08-30 | 2011-02-28 | Кьюрдм, Инк. | Композиции и способы использования проостровковых пептидов и их аналогов |
| WO2009049222A1 (en) * | 2007-10-12 | 2009-04-16 | Curedm, Inc. | Compositions and methods of using the human proislet peptide receptor |
| NO2514436T3 (cg-RX-API-DMAC7.html) | 2007-11-07 | 2018-05-19 | ||
| US20100004213A1 (en) | 2007-11-29 | 2010-01-07 | Abbas Alexander R | Gene expression markers for inflammatory bowel disease |
| KR20110015409A (ko) | 2007-11-29 | 2011-02-15 | 제넨테크, 인크. | 염증성 장 질환에 대한 유전자 발현 마커 |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| WO2009099582A2 (en) | 2008-01-31 | 2009-08-13 | Diakine Therapeutics, Inc. | Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide |
| EP2257814B1 (en) | 2008-03-21 | 2012-08-29 | Podiceps B.v. | Diagnostic of pre-symptomatic metabolic syndrome |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| JP2010085375A (ja) | 2008-10-02 | 2010-04-15 | Nationa Hospital Organization | 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット |
| US20110212104A1 (en) | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US8012928B2 (en) | 2008-12-19 | 2011-09-06 | The Research Foundation Of State University Of New York | Truncated PAP2 and methods of making and using same |
| JP5843357B2 (ja) | 2009-02-03 | 2016-01-13 | アムニクス オペレーティング インコーポレイテッド | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 |
| EP2260857A1 (en) | 2009-06-11 | 2010-12-15 | Alfact Innovation | Novel applications of HIP/PAP or derivatives thereof |
| ES2356217B1 (es) | 2009-08-04 | 2012-02-13 | Universidad De Salamanca | Método para la detección de daño renal. |
| CN102686727A (zh) | 2009-10-09 | 2012-09-19 | 阿纳福公司 | 基于c-型凝集素结构域的组合文库 |
| US20110086770A1 (en) | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Combinatorial Libraries Based on C-type Lectin-like Domain |
| WO2011084808A2 (en) | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| ES2374370B1 (es) | 2010-08-04 | 2013-01-08 | Universidad De Salamanca | Método para la detección de daño renal. |
| CN102827253B (zh) * | 2011-06-17 | 2017-07-21 | 上海市第一人民医院 | 一种抑制炎症反应的小分子多肽及其应用 |
| CN105492459A (zh) * | 2013-02-15 | 2016-04-13 | 高端学术皇家研究会/麦吉尔大学 | 用于治疗糖尿病的修饰的ingap肽 |
-
2013
- 2013-03-15 US US14/775,568 patent/US20160039877A1/en not_active Abandoned
- 2013-03-15 WO PCT/CN2013/072771 patent/WO2014139182A1/en not_active Ceased
-
2014
- 2014-03-14 CA CA2906240A patent/CA2906240C/en active Active
- 2014-03-14 WO PCT/CN2014/073483 patent/WO2014139472A1/en not_active Ceased
- 2014-03-14 NZ NZ711958A patent/NZ711958A/en unknown
- 2014-03-14 MX MX2015012038A patent/MX378245B/es unknown
- 2014-03-14 US US14/417,110 patent/US9388215B2/en active Active
- 2014-03-14 RU RU2015143655A patent/RU2685958C2/ru active
- 2014-03-14 JP JP2015561930A patent/JP6674258B2/ja active Active
- 2014-03-14 BR BR112015022469A patent/BR112015022469A2/pt not_active IP Right Cessation
- 2014-03-14 ES ES14762306T patent/ES2703110T3/es active Active
- 2014-03-14 AU AU2014231444A patent/AU2014231444B2/en active Active
- 2014-03-14 SG SG11201507404RA patent/SG11201507404RA/en unknown
- 2014-03-14 KR KR1020157029362A patent/KR102244349B1/ko active Active
- 2014-03-14 EP EP18196856.1A patent/EP3473642B1/en active Active
- 2014-03-14 EP EP14762306.0A patent/EP2970385B1/en active Active
-
2015
- 2015-09-09 MX MX2019009886A patent/MX2019009886A/es unknown
- 2015-09-09 IL IL241383A patent/IL241383B/en active IP Right Grant
-
2016
- 2016-06-08 US US15/177,206 patent/US9738695B2/en active Active
-
2017
- 2017-07-19 US US15/654,516 patent/US20180009861A1/en not_active Abandoned
-
2018
- 2018-05-29 US US15/992,039 patent/US10899815B2/en not_active Expired - Fee Related
- 2018-10-08 AU AU2018241212A patent/AU2018241212B2/en not_active Ceased
-
2019
- 2019-10-21 US US16/658,218 patent/US20200347106A1/en not_active Abandoned
- 2019-12-13 JP JP2019225049A patent/JP7075918B2/ja active Active
-
2020
- 2020-11-30 AU AU2020280993A patent/AU2020280993B2/en not_active Ceased
-
2022
- 2022-05-18 US US17/747,788 patent/US20220348618A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512205A5 (cg-RX-API-DMAC7.html) | ||
| JP2020062028A5 (cg-RX-API-DMAC7.html) | ||
| Nelke et al. | Skeletal muscle as potential central link between sarcopenia and immune senescence | |
| Liu et al. | A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus | |
| RU2015143655A (ru) | Композиции и способы использования пептидов неогенеза островков и их аналогов | |
| Argilés et al. | Muscle wasting in cancer: the role of mitochondria | |
| Pessina et al. | Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy | |
| JP2015057427A5 (cg-RX-API-DMAC7.html) | ||
| Naranjo et al. | Regenerative medicine approaches for age-related muscle loss and sarcopenia: a mini-review | |
| JP2025163148A (ja) | 不整脈源性右心室心筋症における電気的機能及び心臓機能並びに心構造を回復するための遺伝子療法戦略 | |
| JP2011241213A5 (cg-RX-API-DMAC7.html) | ||
| Hu et al. | Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats | |
| JP2020502140A5 (cg-RX-API-DMAC7.html) | ||
| Alway et al. | The role of mitochondria in mediation of skeletal muscle repair | |
| EP3539537A1 (en) | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash) | |
| CN106279400A (zh) | P8降糖肽的设计及其用途 | |
| Thuy et al. | Novel therapeutic effects of sesamin on diabetes-induced cardiac dysfunction | |
| Hao et al. | Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes | |
| MX2014002155A (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| JP2018503644A5 (cg-RX-API-DMAC7.html) | ||
| JP2019520837A (ja) | Β細胞ミメティック細胞 | |
| BR112020024643A2 (pt) | método de tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2, método de melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, imeglimina para uso em um método para tratamento de pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 de um sujeito, imeglimina para uso em um método para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2, uso de imeglimina para a fabricação de um medicamento para o tratamento de um sujeito tendo pré-diabetes ou diabetes mellitus tipo 1 ou tipo 2 e uso de imeglimina para a fabricação de um medicamento para melhoria do controle glicêmico em um sujeito tendo pré-diabetes ou diabetes tipo 1 ou tipo 2 | |
| Kruczkowska et al. | Senescent adipocytes and type 2 diabetes–current knowledge and perspective concepts | |
| Li et al. | Signal transduction mechanism of exosomes in diabetic complications | |
| JP2016515123A5 (cg-RX-API-DMAC7.html) |